ANEB
Anebulo Pharmaceuticals Inc

188
Loading...
Loading...
News
all
press releases
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
Business Wire·8mo ago
News Placeholder
More News
News Placeholder
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the Company or...
Business Wire·10mo ago
News Placeholder
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
Business Wire·11mo ago
News Placeholder
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
Business Wire·1y ago
News Placeholder
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute...
Business Wire·1y ago
News Placeholder
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB Get Free Report) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 4,600...
Ticker Report·2y ago
News Placeholder
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Declines By 18.2%
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB Get Free Report) was the recipient of a significant decline in short interest in January. As of January 31st, there was short interest totalling...
Ticker Report·2y ago
News Placeholder
Anebulo Pharmaceuticals price target lowered by $2 at Ladenburg, here's why
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
New Debt & Financing Risk for Anebulo Pharmaceuticals, Inc. What's the Latest?
Anebulo Pharmaceuticals, Inc. (ANEB) has disclosed a new risk, in the Debt & Financing category. Anebulo Pharmaceuticals, Inc. has undertaken a sig...
TipRanks Financial Blog·2y ago
News Placeholder
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse...
Business Wire·2y ago

Latest ANEB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.